S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia).

Trial Profile

S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Burkitt's lymphoma; Leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jan 2017 Planned End Date changed from 1 Feb 2019 to 1 Jan 2023.
    • 04 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2022.
    • 12 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top